Rpg Life Sciences Limited · NSE:RPGLIFE
Rpg Life Sciences — RPG Annual Investor Conference 2026
16 slides from Rpg Life Sciences's conference presentation, May 25, 2026
Slide 1: Exchange filing cover letter: Investor Presentation
May 25, 2026 To The Manager BSE Limited Listing Department Corporate Relationship Department National Stock Exchange of India Limited Floor 25, P.J. Towers, Exchange Plaza, 5th Floor, Dalal Street, Plot No. C-1, G- Block, Mumbai 400 001 Bandra - Kurla Complex, Bandra (East) Mumbai – 400 051 Symbol:
Slide 2: RPG Annual Investor Conference 2026
hello happiness RPG Annual Investor Conference 2026 RPG Life Sciences May 26, 2026 1
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Life Sciences: An Integrated Pharmaceutical Company
RPG Life Sciences: An Integrated Pharmaceutical Company RPG Life Sciences is an integrated research based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. Domestic Formulations (DF) Leader in Immunosuppr
Slide 5: RPG Life Sciences: Product Portfolio
RPG Life Sciences: Product Portfolio Strong ‘Textbook’ brands ; ↑ Chronic and Specialty therapies Key Therapies DF Key Products Legacy Portfolio New Portfolio Nephrology Specialty Chronic Immunosuppressants Textbook Brands Life Cycle Management (Existing Products) Rheumatology Trastuzumab Azathiopri
Slide 6: Key Business Highlights
Key Business Highlights
Slide 7: All round performance in FY26 with robust financial metrics
All round performance in FY26 with robust financial metrics 8.3% 24.4% 28.5% Revenue Growth EBITDA % ROCE v/s FY25 Sustained growth momentum to record Strong profitability leading to robust EBITDA Strong return ratios achieved through 707.5 cr. revenue in FY26 generation of 172.7 cr. in FY26 discipl
Slide 8: Consistent Outperformance in Domestic Formulations business
Consistent Outperformance in Domestic Formulations business (69% sales contributor) Sustained Outperformance vs IPM2 Key Business highlights FY 26 17.2 18.2 Full Year DF business grew Emerged in Q4 as the 13.7 1.6x 4th than the market in FY261 fastest growing company in IPM2 10.5 10.1 8.6 9.5 7.7 7.
Slide 9: Domestic Formulations: Strategies that enabled market-beating growth
Domestic Formulations: Strategies that enabled market-beating growth 1 Focus on High Growth • Deepened focus on key therapy baskets like nephro, rheuma, oncology and Therapy pain management recording market-beating growth rates in FY26 2 Strong Brands Gaining • Key brands like Naprosyn grew at marke
Slide 10: Growth & efficiency initiatives for API and International Formulations business
Focusing on growth & efficiency initiatives to drive API and International Formulations business Driving improvement across cost, quality, growth & productivity 1 Building manufacturing 2 Driving Cost 3 Accelerating R&D capacity Efficiency output Implementing further cost optimization Enhancing manu
Slide 11: Financials
Financials
Slide 12: Consistent market-beating growth backed by healthy profitability and cashflows
Consistent market-beating growth backed by healthy profitability and cashflows Rs. crores Revenue growth at 12.7% Consistent focus on improving Significant cash reserves1 5-year CAGR margins and efficiency (from operations) 178.2 707.5 150.3 389.1 53.6 40.3 FY21 FY26 FY21 FY26 FY21 FY26 Consistent m
Slide 13: Continued strengthening of our balance sheet in FY26
Continued strengthening of our balance sheet in FY26 Improvements recorded in Factors affecting rating ICRA Rating affirmation • A robust capital structure and strong debt servicing indicators based on • Long term rating o Healthy cash flows reaffirmed at A+ and outlook retained as stable • Steady g
Slide 14: Continued focus on delivering environmental-friendly growth
Continued focus on delivering environmental-friendly growth 48.5% carbon emission 40% reduction in hazardous reduction in FY26 waste management in FY26 48% improvement in 18% reduction in water energy efficiency in FY26 consumption achieved in FY26 13
Slide 15: RPGLS continues to focus on execution across our strategic framework
RPGLS continues to focus on execution across our well-defined strategic framework Build mega Identifying Build a future Focus on Grow API & IF brands (100+ cr. opportunities for ready business increasing business through Naprosyn), 100+ DF portfolio via strategic capacity entering new cr. Immuno & s
Slide 16: hello happiness
ei hello happiness L MPRPG | recuire sciences
RPG Life Sciences — RPG Annual Investor Conference 2026 on 6ix